This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Adverse Events of Fluoxetine: Postmarketing Compared With Premarketing Clinical Trials

Mahmoud N. Musa and James M. Staneluis

Published: October 31, 2000

Article Abstract

Letter to the Editor

Sir: A prevalent perception exists among clinical pharmacologists and clinicians that the burden of adverse events is higher when a drug is utilized in the natural clinical environment than when used in premarketing clinical trials. The postmarketing study by Zajecka et al., which reported on the adverse events of fluoxetine, affords the opportunity to test this perception.

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 61

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!


Already registered? Sign In

Clinical and Practical Psychopharmacology

Antipsychotic Augmentation With N-Acetylcysteine for Patients With Schizophrenia

Dr Andrade discusses whether or not recent findings support the use of NAC as antipsychotic augmentation in...